Fig. 3.

Anti-CD25 mAb synergistically enhances the antitumor efficacy of gp96 tumor vaccine. Female C57BL/6 J mice were injected subcutaneously with B16.F10 melanoma cells (3 × 10⁴ cells/mouse). When the subcutaneous tumors reached 50 mm³, mice were immunized 4 times with tumor-derived gp96 or liver-derived gp96 vaccine at a 3-day interval or treated with a single dose of anti-CD25 mAb (Anti-CD25) or PBS (PBS) as control on day 0. Some mice given the vaccine were also treated with a single dose of anti-CD25 mAb (B16-gp96+Anti-CD25) or control IgG1 (B16-gp96+IgG1 and Liver gp96+IgG1), or cyclophosphamide (B16-gp96+cy). a Tumor diameter was measured every other day for total of 12 days. Each curve represents the tumor volume in a single mouse. b Tumor weight was measured when mice were killed on day 12. Data show mean ± SD of seven mice. c Kaplan–Meier plot of mouse survival under different treatment. Each treatment group contained 10 mice. Mice were monitored for 50 days for survival. Treatment groups were compared with the log-rank test. **P < 0.01. These experiments were repeated at least twice with comparable results